ERBB2 and breast cancer: In agreement with observations, it is clearly demonstrated that the combination treatment of pyrotinib and chrysin synergistically potentiates autophagy in HER2-positive breast cancer cells via regulating miR-16-5p/ZBTB16/G6PD axis (Fig. 6h).